pubmed.ncbi.nlm.nih.gov

Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review - PubMed

  • ️Tue Jan 01 2019

Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review

Laura Orsolini et al. Medicina (Kaunas). 2019.

Abstract

Background and objectives: Post-traumatic stress disorder (PTSD) is a common psychiatric disorder resulting from a traumatic event, is manifested through hyperarousal, anxiety, depressive symptoms, and sleep disturbances. Despite several therapeutic approaches being available, both pharmacological and psychological, recently a growing interest has developed in using cannabis and synthetic cannabinoids stems from their consideration as more efficient and better tolerated alternatives for the treatment of this condition. The present paper aims to evaluate the clinical and therapeutic potentials of medical cannabis and synthetic cannabinoids in treating PTSD patients.

Methods: A systematic electronic search was performed, including all papers published up to May 2019, using the following keywords (((cannabis[Title/Abstract]) OR (synthetic cannabinoids [Title/Abstract])) AND ((PTSD[Title/Abstract]) OR (Posttraumatic stress disorder[Title/Abstract]))) for the topics 'Cannabis', 'Synthetic Cannabinoids', 'PTSD', and MESH terms, on the PubMed, Cochrane Library, and Web of Science online databases. For data gathering purposes, PRISMA guidelines were followed. Results were organized into two groups, considering cannabis and synthetic cannabinoids as different therapeutic approaches for PTSD.

Results: Present data show that cannabis and synthetic cannabinoids, both acting on the endocannabinoids system, may have a potential therapeutic use for improving PTSD symptoms, e.g., reducing anxiety, modulating memory-related processes, and improving sleep.

Conclusions: Even though the current literature suggests that cannabis and synthetic cannabinoids may have a role in the treatment of PTSD, there is currently limited evidence regarding their safety and efficacy. Therefore, additional research is needed in order to better understand the effectiveness and therapeutic usage of these drug classes and monitor their safety.

Keywords: CBD; PTSD; cannabinoids; cannabis; endocannabinoid system; synthetic cannabinoids; trauma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1

Selection of studies retrieved for the systematic review [35].

Similar articles

Cited by

References

    1. Bitencourt R.M., Takahashi R.N. Cannabidiol as a therapeutic alternative for post-traumatic stress disorder: From bench research to confirmation in human trials. Front. Neurosci. 2018;12:502. doi: 10.3389/fnins.2018.00502. - DOI - PMC - PubMed
    1. Jurkus R., Day H.L.L., Guimares F.S., Lee J.L.C., Bertoglio L.J., Stevenson C.W. Cannabidiol regulation of learned fear: Implications for treating anxiety-related disorders. Front. Pharmacol. 2016;7:454. doi: 10.3389/fphar.2016.00454. - DOI - PMC - PubMed
    1. Shorter D., Hsieh J., Kosten T.R. Pharmacologic management of comorbid post-traumatic stress disorder and addictions. Am. J. Addict. 2015;24:705–712. doi: 10.1111/ajad.12306. - DOI - PubMed
    1. Bailey C.R., Cordell E., Sobin S.M., Neumeister A. Recent Progress in Understanding the Pathophysiology of Post-Traumatic Stress Disorder Implications for Targeted Pharmacological Treatment. CNS Drugs. 2013;27:221–232. doi: 10.1007/s40263-013-0051-4. - DOI - PMC - PubMed
    1. Shishko I., Oliveira R., Moore T.A., Almeida K. A review of medical marijuana for the treatment of post-traumatic stress disorder: Real symptom re-leaf or just high hopes? Ment. Health Clin. 2018;8:86–94. doi: 10.9740/mhc.2018.03.086. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances